

The Edinburgh Consensus: preparing for the advent of Alzheimer's disease

Alzheimer's Research and Therapy

9, 85

DOI: [10.1186/s13195-017-0312-4](https://doi.org/10.1186/s13195-017-0312-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 285-300.	1.2	27
2	Integrated care for adults with dementia and other cognitive disorders. <i>International Review of Psychiatry</i> , 2018, 30, 272-291.	1.4	24
3	Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer's Disease. <i>CNS Drugs</i> , 2018, 32, 1085-1090.	2.7	4
4	Alzheimer's disease (AD) therapeutics 2: Beyond amyloid Re-defining AD and its causality to discover effective therapeutics. <i>Biochemical Pharmacology</i> , 2018, 158, 376-401.	2.0	24
5	Relevance of Coded Prodromal Mild Cognitive Impairment in the Routine Treatment of Patients with Dementia in Germany. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 393-399.	1.2	3
6	The Erlangen test of activities of daily living in persons with mild dementia or mild cognitive impairment (ETAM) an extended validation. <i>BMC Psychiatry</i> , 2018, 18, 308.	1.1	6
8	Donepezil for dementia due to Alzheimer's disease. <i>The Cochrane Library</i> , 2018, 2018, CD001190.	1.5	377
9	Tackling gaps in developing life-changing treatments for dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 241-253.	1.8	17
10	Coded Prevalence of Mild Cognitive Impairment in General and Neuropsychiatrists Practices in Germany Between 2007 and 2017. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1313-1318.	1.2	6
11	Neuropsychological assessment in preclinical and prodromal Alzheimer disease: a global perspective. <i>Journal of Global Health</i> , 2019, 9, 010317.	1.2	15
12	A practical computerized decision support system for predicting the severity of Alzheimer's disease of an individual. <i>Expert Systems With Applications</i> , 2019, 130, 157-171.	4.4	73
13	Diagnostic Behavior for Mild Cognitive Impairment in General and Neuropsychiatric Practices in Germany. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 925-930.	1.2	5
14	What matters to people with memory problems, healthy volunteers and health and social care professionals in the context of developing treatment to prevent Alzheimer's dementia? A qualitative study. <i>Health Expectations</i> , 2019, 22, 504-517.	1.1	15
15	Healthcare Models in Alzheimer's Disease. , 2019, , .		0
16	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019, 15, 388-399.	0.4	37
17	A mixed methods systematic review of multimodal non-pharmacological interventions to improve cognition for people with dementia. <i>Dementia</i> , 2020, 19, 1086-1130.	1.0	51
18	RATIONALE FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI) SUPPORTED BY EMERGING DIGITAL TECHNOLOGIES. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2020, 7, 1-7.	1.5	37
19	Cu ²⁺ -Regulated reversible coordination interaction of GQD@Tb/GMP ICP nanoparticles: towards directly monitoring cerebrospinal acetylcholinesterase as a biomarker for cholinergic brain dysfunction. <i>Analyst</i> , The, 2020, 145, 7849-7857.	1.7	3

#	ARTICLE	IF	CITATIONS
20	Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer's disease. <i>Life Sciences, Society and Policy</i> , 2020, 16, 11.	3.1	4
21	Characterization and evaluation of porous hydroxyapatite synthesized by oil-in-water method as carrier of donepezil for the preventive of Alzheimer's disease by controlled release. <i>Journal of Asian Ceramic Societies</i> , 2020, 8, 1216-1227.	1.0	4
22	Amyloid PET imaging in clinical practice. <i>Practical Neurology</i> , 2020, 20, 451-462.	0.5	28
23	Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12081.	1.2	28
24	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. <i>Alzheimer's and Dementia</i> , 2020, 16, 1457-1468.	0.4	43
26	Sport associated dementia. <i>BMJ, The</i> , 2021, 372, n168.	3.0	4
27	A UK-Wide Study Employing Natural Language Processing to Determine What Matters to People about Brain Health to Improve Drug Development: The Electronic Person-Specific Outcome Measure (ePSOM) Programme. <i>Journal of prevention of Alzheimer's disease, The</i> , 2021, 8, 1-9.	1.5	3
28	Alzheimer's disease research: past approaches and future directions. <i>British Journal of Neuroscience Nursing</i> , 2021, 17, 34-39.	0.1	0
30	Mild cognitive impairment history and current procedures in low- and middle-income countries: a brief review. <i>Dementia E Neuropsychologia</i> , 2021, 15, 155-163.	0.3	4
31	Validity and Cultural Generalisability of a 5-Minute AI-Based, Computerised Cognitive Assessment in Mild Cognitive Impairment and Alzheimer's Dementia. <i>Frontiers in Psychiatry</i> , 2021, 12, 706695.	1.3	25
32	Lived time and the affordances of clinical research participation. <i>Sociology of Health and Illness</i> , 2021, , .	1.1	2
33	Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management. <i>Frontiers in Neurology</i> , 2020, 11, 592302.	1.1	23
34	Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12184.	1.2	10
35	Abnormalities of saccadic eye movements in dementia due to Alzheimer's disease and mild cognitive impairment. <i>Aging</i> , 2019, 11, 5389-5398.	1.4	51
37	THE ROLE OF CLINICAL TRIALS IN PRECLINICAL ALZHEIMER'S DISEASE DRUG DEVELOPMENT PROGRAMS. <i>Journal of prevention of Alzheimer's disease, The</i> , 2020, 7, 1-3.	1.5	1
38	Differences in care between younger and older patients in the 2019 English national memory service audit. <i>BJPsych Bulletin</i> , 2022, 46, 315-321.	0.7	2
39	Assessing and disclosing test results for "mild cognitive impairment": the perspective of old age psychiatrists in Scotland. <i>BMC Geriatrics</i> , 2022, 22, 50.	1.1	5
40	Diagnosing Alzheimer's Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1721-1734.	1.2	3

#	ARTICLE	IF	CITATIONS
41	From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?. , 2022, , 343-353.		1
42	The European Prevention of Alzheimerâ€™s Disease Program: A Publicâ€“Private Partnership to Facilitate the Secondary Prevention of Alzheimerâ€™s Disease Dementia. , 2022, , 190-206.		1
45	Diagnostic accuracy of CompCog: reaction time as a screening measure for mild cognitive impairment. Arquivos De Neuro-Psiquiatria, 2022, 80, 570-579.	0.3	1
46	Designing the next-generation clinical care pathway for Alzheimerâ€™s disease. Nature Aging, 2022, 2, 692-703.	5.3	44
47	The European Prevention of Alzheimer's Dementia Programme: An Innovative Medicines Initiative-funded partnership to facilitate secondary prevention of Alzheimer's disease dementia. Frontiers in Neurology, 0, 13, .	1.1	2
48	An anti-amyloid therapy works for Alzheimerâ€™s disease: why has it taken so long and what is next?. Brain, 2023, 146, 1240-1242.	3.7	15